SunTrust Banks Comments on Spark Therapeutics Inc’s FY2018 Earnings (ONCE)

Spark Therapeutics Inc (NASDAQ:ONCE) – Investment analysts at SunTrust Banks decreased their FY2018 earnings per share (EPS) estimates for Spark Therapeutics in a research report issued on Tuesday, November 6th. SunTrust Banks analyst E. Nash now anticipates that the biotechnology company will post earnings per share of ($1.58) for the year, down from their prior forecast of ($0.94). SunTrust Banks currently has a “Buy” rating and a $61.00 price target on the stock. SunTrust Banks also issued estimates for Spark Therapeutics’ Q4 2018 earnings at ($1.21) EPS, Q1 2019 earnings at ($1.10) EPS, Q2 2019 earnings at ($1.13) EPS, Q3 2019 earnings at ($1.04) EPS, Q4 2019 earnings at ($1.01) EPS, FY2019 earnings at ($3.59) EPS, FY2020 earnings at ($3.44) EPS, FY2021 earnings at ($3.16) EPS and FY2022 earnings at ($1.21) EPS.

Several other brokerages have also commented on ONCE. ValuEngine lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. UBS Group decreased their price objective on shares of Spark Therapeutics from $80.00 to $53.00 and set a “neutral” rating for the company in a research report on Wednesday, August 8th. William Blair reaffirmed a “buy” rating on shares of Spark Therapeutics in a research report on Friday, September 21st. Raymond James set a $82.00 price objective on shares of Spark Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 8th. Finally, Mizuho reaffirmed a “buy” rating and issued a $77.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $68.52.

Shares of Spark Therapeutics stock opened at $46.00 on Friday. The company has a market capitalization of $1.57 billion, a P/E ratio of -6.03 and a beta of 2.27. Spark Therapeutics has a 52 week low of $39.01 and a 52 week high of $96.59.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.04) by ($0.22). Spark Therapeutics had a negative net margin of 127.82% and a negative return on equity of 14.34%. The firm had revenue of $10.70 million during the quarter, compared to the consensus estimate of $27.44 million. During the same quarter in the prior year, the business posted ($1.90) earnings per share. The firm’s quarterly revenue was up 463.2% on a year-over-year basis.

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. grew its stake in Spark Therapeutics by 42.7% in the 1st quarter. Russell Investments Group Ltd. now owns 19,942 shares of the biotechnology company’s stock valued at $1,328,000 after acquiring an additional 5,969 shares during the period. Millennium Management LLC acquired a new stake in Spark Therapeutics in the 1st quarter valued at $1,578,000. Fox Run Management L.L.C. acquired a new stake in Spark Therapeutics in the 2nd quarter valued at $533,000. Amalgamated Bank grew its stake in Spark Therapeutics by 29.7% in the 2nd quarter. Amalgamated Bank now owns 4,799 shares of the biotechnology company’s stock valued at $397,000 after acquiring an additional 1,100 shares during the period. Finally, Aperio Group LLC grew its stake in Spark Therapeutics by 23.5% in the 2nd quarter. Aperio Group LLC now owns 5,543 shares of the biotechnology company’s stock valued at $459,000 after acquiring an additional 1,056 shares during the period.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Read More: How Do You Calculate Return on Investment (ROI)?

Earnings History and Estimates for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply